Drug company AbbVie has agreed to buy biotech ImmunoGen for $10.1 billion in a fresh bet on one of the most promising new technologies for attacking cancer.

ImmunoGen develops cancer drugs called antibody-drug conjugates, or ADCs, which work like guided missiles delivering a toxic agent directly to tumors. The technology is among the hottest areas in the pharmaceutical industry. Recent advancements have spread its use to common kinds of cancer such as breast, spawning other multibillion deals.